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1  Introduction
Bioethics has evolved from a discipline mostly perceived as 
being focused on moral issues ranging from medical practice 
to a wider endeavor where concerns regarding the nature 
of human identity, animal welfare and the environment 
are becoming increasingly important, if not central. This is 
the result of the unrelenting pace at which the life sciences 
and biotechnology are advancing, defying old paradigms 
and creating new ones. The past 20 years have witnessed 3 
milestones in the life sciences; the birth of the first cloned 
mammal, Dolly (Callaway 2016), the completion of the 
Human Genome Project (Venter et al. 2001) and the discovery 
and harnessing of CRISPR, a game changer in the field of 
genome editing (Mariscal and Petropanagos 2016).
The main goal of biotechnology is and has always been 
to improve people’s lives; this is in line with ethical goals 
and is in itself an ethical vision. Animal domestication, 
agriculture and fermentation, all contributed to a 
better quality of life with the consequent expansion of 
human population through the planet. More recently, 
technological and medical advances such as nitrogen 
fixation, vaccines and antibiotics have contributed to a 
longer life expectancy and population explosion arising 
important issues, perhaps the most important the 
allocation of resources in a world edging close to ecological 
exhaustion. It is to be expected that many of the emerging 
biotechnologies of today will become an established part 
of daily life in the future. But will these changes be positive 
for society? Have the risks and benefits been analysed? 
All these changes often occur without consultation with 
the general population, and sometimes without ethical 
reflection on the part of the scientists and technologists 
involved (O’Mathúna 2007). 
2  Biotechnology: the road to 
genetic engineering
The history of biotechnology can be roughly divided 
into three categories: Ancient Biotechnology, Classical 
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not exclusively, around themes of moral importance for the 
medical practice, such as abortion and euthanasia, a never 
ending discussion that has been shaped by social mores and 
influenced by scientific and technological advance. However, 
in the past 20 years an important shift has been taking place, 
one where bioethical issues and their discussion are starting 
to being driven by the so-called emerging biotechnologies, 
from cloning to genome sequencing and editing. If Bioethics 
is concerned with human beings, and their interaction with 
other living beings and the environment, it makes sense for 
Biotechnology, by definition the use of living systems or 
organisms to develop products, to become an important, 
if not the most important, source of bioethical conflicts in 
modern era and for future society. As Biotechnology keeps 
expanding and becomes entangled in everyday life, so 
does the need for ethical competent biotechnologists, with 
competencies built not only on ethical principles but also on 
a realistic grasp of the impact these technologies could have 
on human society and the world we inhabit.
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Figure 1:  Genetic engineering (GE) involves the manipulation and/
or modification of the genome of living beings, for 3 decades recom-
binant DNA remained the main tool of GE but recently, engineered 
endonucleases (GEEN) such as ZFNs and TALENs have proved to 
be a more precise and efficient tool, the discovery of the CRISPR/
Cas9 system took this one step further, revolutionizing GE. To 
differentiate from recombinant DNA technology, the modification of 
genomes using endonucleases is known as genome editing. Despite 
not involving modification of the genome, cloning is considered by 
many a type of GE
CRISPR stands for Clustered regularly interspaced 
short palindromic repeats, short snippets of viral DNA 
inserted into a bacterial genome, acting as spacers 
and working as a template to synthesize a type of 
interference RNA, able to recognize specific points 
in the genome of an infecting virus to mark sites to 
be cut by nucleases (Gaj et al. 2013). Cas9 is the most 
recognized of these nucleases, but others, such as 
Cpf1, have been recently discovered, expanding the 
toolbox of genetic engineering. If recombinant DNA 
technology was a step forward, CRISPR could be 
described as a quantum leap for genetic engineering 
and for the emerging biotechnologies of transgenic 
plant and animal development, synthetic biology, 
nanotechnology, xenotransplantation, gene therapy 
and population control through gene drives. These 
so-called emerging biotechnologies represent the next 
stage in the development of Biotechnology one that 
now aspires not only to use living beings to develop 
products, but also to tailor organisms through genome 
editing or synthetic biology approaches, to obtain 
new products for human use and consumption. These 
technologies make the ethical training of students and 
Biotechnology and Modern Biotechnology. While 
ancient biotechnology can be described as a series of 
developments, such as the domestication of plants and 
animals and sometimes accidental discoveries, like 
bread, cheese and wine, Classical Biotechnology lingers 
as a transitional period were the fundamental tenets of 
genetics and molecular biology were established. Modern 
Biotechnology officially started from the second half of 
the 20th century with the development of tools for the 
manipulation of nucleic acids, cloning and recombinant 
DNA technology (rDNA), critical for the development of 
genetic engineering (Verma et al. 2011). It is interesting to 
note that Bioethics and Modern Biotechnology were born 
around the same time and although there is discrepancy 
regarding the origin of the word “bioethics” there is 
agreement it was coined between 1970 and 1972 (Pellegrino 
1999; Martensen 2001). In 1972, Paul Berg created the first 
recombinant DNA molecule; the next year Boyer and 
Cohen created the first genetically modified organism, 
these events marked the birth of genetic engineering as a 
force for technological advance (Giassetti 2013). 
For almost three decades, up to 2012, recombinant 
DNA technology had proved to be a solid tool for genetic 
engineering. Despite  limitations: time-consuming, lacks 
precision, low efficiency and high costs, it remained for 
many years the backbone of genetic engineering, along 
with DNA sequencing and the Polymerase Chain Reaction 
(PCR). Given the limitations of the technique, rDNA was 
better suited for single cell organisms and bacteria, and 
since the 1970’s a vast array of medical and industrial 
applications have been developed: human insulin and 
growth hormone-producing recombinant bacteria being 
among the most important. Recombinant DNA technology 
also became a tool for research in laboratories around the 
world.  
Genome editing as a new approach in genetic 
engineering started to develop recently and aim to 
manipulate the genome by adding, subtracting or 
replacing genes inducing site-specific breaks in the DNA 
using nucleases, enzymes able to cut DNA, and taking 
advantage of the natural DNA repair system to close the 
gap. Zinc-finger nucleases (ZFN) were discovered in 2002, 
followed by transcription activator-like effector nucleases 
(TALENs), which represented a significant advance in 
the ability to control the manipulation of DNA. However, 
despite the improvement in precision, both ZFN and 
TALENs still needed significant expertise and resources, 
limiting widespread use. This all changed with the 
discovery of CRISPR/Cas9, a natural system of bacterial 
defense against bacteriophages, reinvented as a precision 
tool for the editing of the genome (Maxmen 2015; Au 2015)
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4  Ethical reflection in 
Biotechnology
The four ethical principles are useful for the discussion of 
the many challenges brought by emerging biotechnologies, 
particularly DNA-based technologies. The first ethical 
principle is beneficence, a moral imperative to contribute 
to other people’s well-being. To act on this principle 
demands a decision of what is good for others; it also 
requires respecting other people’s autonomy, and honour 
individual requests. The principle of non-maleficence 
(Primum non nocere) asks us to not harm others; we should 
avoid needless harm or injury, by omission or action. 
The principle of justice is an essential requirement, 
it demands the fair treatment of individuals, fair access 
to treatment and distribution of resources regardless of 
social status, age, ethnic background, sexual orientation, 
disability, legal capacity and gender. This is what we 
mean by ‘fairness’. Autonomy is based on the idea that 
humans are capable to direct their life in a rational way 
and have the right to do so; another way to express this 
principle is the ability to take decisions regarding one’s 
well-being and fate without external influences (Lawrence 
2007). In medical practice, where the well-being of 
patients is at stake, the four principles can be applied 
with relative unambiguity, in biotechnology, however, 
there are many instances where their use and value is not 
very clear and other considerations must be taken, such 
as risk analysis. Since there is a vast amount of literature 
addressing ethical issues surrounding designer babies, 
gene therapy, xenotransplants, synthetic biology and 
direct-to-consumer genetic testing, the aim of this paper is 
to bring attention to some issues where the use of the four 
principles may prove enlightening.
5  Animal Cloning
This year marks the 20th anniversary of the birth of 
Dolly, the cloned sheep, a landmark event for genetic 
engineering and the life sciences. Dolly lived a mere 6 
years before being put down for health reasons but four 
of her sister clones are still alive and thriving (Sinclair 
et al. 2016). Early cloning success brought focus to bear 
on reproductive human cloning and the ethical issues 
regarding human identity, autonomy and rights, and 
there remains agreement that human cloning should not 
be pursued. This does not mean that reproductive cloning 
professionals of biotechnology in general even more 
urgent (Rasmussen and Ebbesen 2014).
Figure 2: Since the discovery of the CRISPR/Cas9 system in 2012, 
genome editing has become an intense field of research; this is 
evident after reviewing the increment in publications involving this 
technology in recent years. The data shows the number of publica-
tions in 5 different fields where CRISPR/Cas9 was involved; research 
on disease being the most sought application of CRISPR/Cas9. The 
search was performed using PubMed, data was retrieved between 
November 28th and December 5 of 2016. Key words included CRISPR, 
and the combination of CRISPR plus cancer/gene therapy/HIV/crops 
or ethics
3  Emerging biotechnologies
Technology typically advances step by step, but 
occasional more rapid progress can be almost disruptive. 
All emerging technologies have one key feature in common 
despite being diverse in nature and purpose, they  have 
potential to change the status quo. Other features are 
related to their stage of development, their novelty and 
potential risks. Emerging technologies include among 
others, artificial intelligence, 3D printing, robotics and 
a vast array of biotechnology disciplines. According to 
the Nuffield Council for Bioethics (Nco B 2012), there 
are a few key areas that can be identified as particularly 
significant: regenerative medicine, genomic medicine, 
synthetic biology and nanotechnologies, particularly 
nanomedicine. Besides their disruptive nature and 
potential, these emerging biotechnologies also pose 
unknown risks to humans and the environment, risks that 
need first to be assessed  according to best ethical and 
biosafety and biosecurity guidelines. 
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6  Bioterrorism
Biosafety sets out measures to prevent the unintentional 
release or exposure to pathogenic or genetically modified 
organisms (GMO) whereas biosecurity measures are 
directed at preventing the intentional, unauthorized 
access or release of these entities (Kumar 2015). 
Bioterrorism is the use of pathogenic microorganisms or 
infected materials to cause terror and death in targeted 
populations. It has a long history, but it was after the 
terrorist anthrax attacks to the city of New York in 2001 
that concerns around biological threats increased 
significantly. There is no ambiguity regarding the use 
of biotechnology for these aims, the principle of non-
maleficence should be followed. The response to acts of 
bioterrorism is called biodefense, and it is a good example 
of a concept known as dual-use, according to which 
some technologies developed for military pursuits can be 
useful for civilian purposes. In this sense, a lot of research 
involving pathogenic microorganisms is performed in 
military facilities across the United States, justified by the 
search for preventive measures against biological warfare. 
However there are ethical issues concerning the diversion 
of government funds from public health, risks derived 
from facilities close to populated areas and the restriction 
on publication of the research performed in these 
facilities (King 2005). CRISPR technologies add another 
dimension to this problem. As a tool for genome editing; 
CRISPR is more efficient, cheaper and easier to master 
than previous genetic engineering tools, giving upsurge 
in numbers of biohackers, amateurs working outside 
official institutions, yet posing problems of biosafety and 
biosecurity since their activities escape regulation and 
government surveillance (Ledford 2015).
7  Biopiracy (theft of traditional 
knowledge)
The wealth of nations can be measured in terms of 
their biodiversity; those indigenous animals, plants; 
microorganisms which represent an important source 
of new compounds and biomaterials with potential to 
combat emerging diseases or to produce valuable goods. 
South America is perhaps the most rich in biodiversity, 
for example in Brazil, an emerging economy.  This 
biodiversity is an asset coveted by the industrialized 
nations, giving rise to the upsurge of bioprospecting, 
the identification and commercialization of natural 
resources as bioproducts. However, there is a dark side 
to this activity, known as biopiracy, the illegal and 
has been abandoned as a scientific and business pursuit 
and at least 20 distinct animal species have been cloned 
to this day. There is a scene in the movie The 6th Day 
(Spottiswoode 2000), where Johnny Phoenix, a famous 
pro football player, is severely injured during a game 
and is taken to hospital. after a brief phone exchange a 
representative of the owners of Johnny’s contract shuts 
down the machine keeping him alive. Johnny is then 
replaced by a clone of himself, in his world human cloning 
is illegal but is still being done, while animal cloning 
is acceptable and is profitable business. According to 
Vanity Fair’s article How Champion-Pony Clones Have 
Transformed the Game of Polo, in Argentina, Crestview 
Genetics offers to produce exact genetic duplicates of 
an original animal; their business being oriented to the 
cloning of polo champion horses. Also in Argentina, a 
family paid between $60,000 and 100,000 USD to get a 
clone of their deceased pet, a first for the country. Cloning 
has gone commercial and there is a renewed optimism 
and interest in this technology. The fact that animals 
rather than humans are being cloned should not be 
dismissed as unimportant, as from an ethical point of 
view there are issues to be addressed. Cloning animals 
to win trophies, and perhaps money, raises issues of 
justice, not everybody is in a position to pay for such 
services and those with money have a greater chance at 
winning. Something similar can be said of cloning dead 
pets, only for those who can afford it, but most troubling is 
the idea of rejecting death as a part of the life experience. 
So the benefit of cloning pets seems to be more a human 
indulgence and is not a rational, ethical act.
Figure 3: There are four ethical principles that may be used as guide-
lines to assess the ethical issues arising from biotechnology. In this 
figure, emerging biotechnologies were assigned to one of the four 
principles against which ethical issues have been identified (SynBio 
stands for Synthetic Biology)
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9  Concluding Remarks
Biotechnologists are at the front line of a life sciences 
revolution that will ultimately shape the society of the 
future. DNA-based biotechnology has become central to 
technological advancement and progress. It is important 
then, for professionals in this discipline, to be aware of 
the potential consequences of their scientific endeavors 
on society and the individual. For the many challenges 
arising from basic or applied biotechnology, we can use 
the four principles of ethics for discussion and analysis. 
Taking them as a guideline, one could easily advice against 
the use of biotechnology tools for weapon development 
in bioterrorism, do not harm. However, for many other 
issues, resolution and governance may not come easily, 
this can be exemplified by the issues raised by the cloning 
of animals for profit or personal satisfaction. Regarding 
issues of justice, it is important to stress that while the 
primary concerns of the developed world are currently 
focused on human genome editing, these concerns, 
although valid for emerging economies too, overshadow 
other bioethical issues more immediate in their urgency, 
such as population control and biopiracy, where the 
imbalance of economic and political power plays a 
significant role. Biotechnology is growing at a fast pace in 
the developing world, hence, it is important to be aware 
and proficient to assess the impact of biotechnological 
advance in the light of local values and needs.
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